AR/BRD4 RIPTAC-1 TFA 

AR/BRD4 RIPTAC-1 (Compound II-5) TFA is an orally active Regulatory-inducible proximity-targeting chimera (RIPTAC). AR/BRD4 RIPTAC-1 TFA induces the formation of a stable ternary complex between the androgen receptor (AR) and BRD4, thereby blocking BRD4 function. AR/BRD4 RIPTAC-1 TFA inhibits the growth and proliferation of tumor cells. AR/BRD4 RIPTAC-1 TFA holds promise for use in prostate cancer research^[1].

AR/BRD4 RIPTAC-1 (72 h) TFA inhibits the growth of T47D cells with a GI₅₀ of less than 0.5 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

AR/BRD4 RIPTAC-1 (p.o.; 7 days) TFA inhibits tumor growth in CB17.SCID mice bearing VCaP tumors^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1021.12

C₅₂H₅₅F₃N₁₀O₇S

Solid

CC1=NN=C2N1C3=C(C(C)=C(C)S3)C(C4=CC=C(OC5CC6(CCN(C7=NC=C(C(N[C@H]8C(C)(C)[C@H](OC9=CC=C(C(OC)=C9)C#N)C8(C)C)=O)C=N7)CC6)C5)C=C4)=N[C@H]2CC%10=NC=CO%10.O=C(O)C(F)(F)F

Room temperature in continental US; may vary elsewhere.

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

• [1]. Kyle J. Eastman, et al. Heterobifunctional compounds and methods of treating disease. WO2025085738A1. 2025-04-24.